Ophthalmic Pharmaceutical Company, Aerie Pharmaceuticals that seeks to treat patients with open-angle glaucoma and other diseases of the eye declared the appointment of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance. Mr. Hauptmann will support the preparation of regulatory and clinical documents along with oversight of post-marketing pharmacovigilance and promotional activities. Mr. Hauptmann formerly held related positions at Avanir Pharmaceuticals, Inc. and Fibrogen, Inc.
In addition to his appointment, Tim Swan has been appointed as Director of Sales and Transparency Operations. Mr. Hauptmann and Mr. Swan on a combined basis will receive awards totaling 28,800 stock options. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting notably on each of the subsequent 36 monthly anniversaries of the hire date.